Naloxone: Uses, Dosage & Side Effects

What Is Naloxone and What Is It Used For?

Naloxone is an opioid antagonist medication used for the emergency treatment of known or suspected opioid overdose. It works by competitively binding to opioid receptors in the brain, displacing opioid drugs and rapidly reversing their life-threatening effects, particularly respiratory depression.

Naloxone (brand names include Narcan, Nyxoid, and Respinal) belongs to a class of medications called opioid antagonists. It has been used in clinical medicine since the early 1970s and is included on the World Health Organization (WHO) Model List of Essential Medicines, recognizing its critical importance in global health. The medication is effective against all opioid drugs, including morphine, heroin (diamorphine), fentanyl, oxycodone, methadone, and buprenorphine.

The primary use of naloxone is as an emergency antidote for opioid overdose. When a person overdoses on opioids, the drugs suppress the brain's respiratory center, causing breathing to slow or stop entirely. Without intervention, this respiratory depression leads to oxygen deprivation, brain damage, and death within minutes. Naloxone reverses this process by physically displacing opioid molecules from their receptors, restoring normal breathing and consciousness.

Naloxone is available as a nasal spray and as a solution for injection (intravenous, intramuscular, or subcutaneous). The nasal spray formulation has revolutionized overdose response by enabling lay bystanders, family members, and first responders to administer the medication without any medical training or needle use. In the United States, the FDA approved over-the-counter (OTC) naloxone nasal spray in March 2023, making it available in pharmacies without a prescription.

How does naloxone work?

Naloxone is a pure competitive antagonist at opioid receptors, primarily the mu (μ) receptor, which is the main receptor responsible for the euphoric, analgesic, and respiratory depressant effects of opioids. When administered, naloxone has a higher affinity for these receptors than most opioid agonists, meaning it can rapidly displace opioid molecules already bound to the receptors.

This displacement reverses all opioid effects, including respiratory depression, sedation, and hypotension. The onset of action depends on the route of administration: intranasal naloxone typically begins working within 2-5 minutes, while intravenous administration produces effects within 1-2 minutes. The duration of action is approximately 30-90 minutes, which is critically important because many opioids have a longer duration of action than naloxone.

Signs of opioid overdose

Recognizing the signs of opioid overdose is essential for timely naloxone administration. The following are the hallmark signs that indicate a person may be experiencing an opioid overdose:

• Unconsciousness or extreme drowsiness — the person does not respond to loud sounds, shouting their name, or physical stimulation
• Slow, shallow, or absent breathing — fewer than 8 breaths per minute, or long pauses between breaths
• Snoring or gurgling sounds — often mistaken for normal sleeping, these sounds indicate airway obstruction
• Blue or purple discoloration — of fingernails, lips, or skin (cyanosis), indicating oxygen deprivation
• Pinpoint pupils — very small, constricted pupils that do not respond to light
• Limp body — muscles are completely relaxed and the person cannot support themselves
• Slow or irregular pulse — heartbeat may be weak or difficult to find

What Should You Know Before Taking Naloxone?

Naloxone should not be used if you are allergic to naloxone hydrochloride or any of its inactive ingredients. In opioid-dependent individuals, naloxone may cause acute withdrawal syndrome. The effects of some opioids may outlast naloxone, requiring repeated doses and continuous monitoring.

Contraindications

The only absolute contraindication to naloxone use is a known allergy to naloxone hydrochloride or any of the excipients in the formulation. Given that opioid overdose is a life-threatening emergency, there are effectively no other contraindications that should prevent its use when overdose is suspected. The benefit of reversing potentially fatal respiratory depression far outweighs any potential risks.

It is worth noting that some naloxone nasal spray formulations contain benzalkonium chloride as a preservative. This excipient can cause nasal irritation and swelling, particularly with prolonged or repeated use. However, this should not be a reason to withhold naloxone in an overdose emergency.

Warnings and Precautions

While naloxone itself has an excellent safety profile, there are several important warnings and precautions that users and caregivers should be aware of:

Acute opioid withdrawal syndrome: In individuals who are physically dependent on opioids (whether through prescribed use or illicit use), naloxone may precipitate acute withdrawal syndrome. This occurs because naloxone rapidly displaces opioids from their receptors, abruptly ending the body's exposure to the drugs it has become dependent upon. Withdrawal symptoms can include:

• Rapid heart rate and elevated blood pressure
• Body aches, muscle cramps, and abdominal pain
• Nausea, vomiting, and diarrhea
• Sweating, fever, and goosebumps
• Trembling, shaking, or seizures
• Agitation, irritability, anxiety, and restlessness
• Behavioral changes, including potential aggression
• Difficulty sleeping and increased pain sensitivity

Despite the discomfort of withdrawal, it is far less dangerous than untreated opioid overdose. The reversal of respiratory depression is the primary goal of naloxone administration, and withdrawal symptoms, while unpleasant, are manageable with appropriate medical support.

Recurrence of opioid effects: This is perhaps the most critical warning. Naloxone has a shorter duration of action (30-90 minutes) than many opioids, particularly long-acting opioids such as methadone, extended-release oxycodone, or fentanyl. This means that after naloxone wears off, the opioid effects can return, potentially causing respiratory depression again. This is why it is essential to always call emergency services and monitor the individual continuously, even if they appear to have fully recovered.

Buprenorphine partial reversal: Naloxone may not fully reverse the respiratory depression caused by buprenorphine (a partial opioid agonist) because buprenorphine has an extremely high binding affinity for opioid receptors. Higher or repeated doses of naloxone may be necessary when buprenorphine is involved.

Nasal conditions: Individuals with nasal injuries, nasal surgery, or significant nasal congestion may have altered absorption of intranasal naloxone. If nasal spray administration is not effective, alternative routes (intramuscular injection) should be considered by emergency responders.

Pregnancy and Breastfeeding

In a life-threatening overdose situation, naloxone should be administered regardless of pregnancy status. The risk of maternal and fetal death from untreated opioid overdose far outweighs the potential risks of naloxone. However, naloxone may precipitate opioid withdrawal in both the mother and the fetus, which can potentially cause fetal distress, premature labor, or miscarriage in severe cases.

If naloxone is administered to a pregnant woman, both the mother and baby should be closely monitored by healthcare professionals. Women who are pregnant and prescribed opioids should discuss naloxone access with their healthcare provider as part of a comprehensive risk management plan.

For breastfeeding mothers, the decision to breastfeed after naloxone administration should be made in consultation with a healthcare provider. Naloxone has a short half-life and is rapidly metabolized, but the underlying opioid exposure may also be a consideration.

Driving and Operating Machinery

After receiving naloxone for an opioid overdose, individuals should not drive, operate heavy machinery, or engage in any physically or mentally demanding activities for at least 24 hours. This precaution is necessary because opioid effects may return once naloxone wears off, and cognitive and motor functions may remain impaired even after apparent recovery.

Use in Children and Adolescents

The nasal spray formulations described in this article (such as Respinal/Ventizolve 1.26 mg) are specifically approved for use in adults. They should not be used in children and adolescents. Pediatric-specific naloxone formulations and dosing exist for healthcare settings. If a child is suspected of opioid exposure, call emergency services immediately.

How Does Naloxone Interact with Other Drugs?

Naloxone directly antagonizes the effects of all opioid drugs, including morphine, heroin, fentanyl, oxycodone, methadone, and buprenorphine. When used in patients taking opioids for chronic pain, naloxone will reverse pain relief. Combined opioid-alcohol intoxication may delay naloxone's onset of action.

Naloxone's mechanism of action means that its primary interactions are with opioid medications and substances. Because naloxone is a competitive antagonist at opioid receptors, it will oppose the effects of any opioid agonist or partial agonist. Unlike many other medications, naloxone does not have significant metabolic drug interactions through the cytochrome P450 enzyme system. Its interactions are pharmacodynamic rather than pharmacokinetic.

Major Interactions

The most clinically significant interactions occur when naloxone is administered to patients who are physically dependent on opioids or who are receiving opioid therapy for pain management.

Minor Interactions

Naloxone has no clinically significant interactions with non-opioid medications. It does not interact with benzodiazepines, stimulants, anticonvulsants, antidepressants, or cardiovascular medications. This favorable interaction profile is one reason why naloxone is considered safe for over-the-counter availability.

However, it is important to understand that naloxone cannot reverse the effects of non-opioid substances. In mixed overdoses involving both opioids and benzodiazepines or alcohol, naloxone will only reverse the opioid component. The sedation and respiratory depression caused by other substances will persist and require separate medical management.

If the person takes opioids for management of chronic pain, they should be aware that naloxone administration will also reverse pain-relieving effects, potentially resulting in the return of severe pain. This does not mean naloxone should be withheld in an emergency, but healthcare providers should be prepared to manage pain through non-opioid means once the emergency is resolved.

What Is the Correct Dosage of Naloxone?

For intranasal naloxone, one spray (1.26 mg or 1.8 mg depending on the product) is administered into one nostril. If there is no improvement after 2-3 minutes, a second dose can be given in the other nostril using a new device. For injectable naloxone, the typical starting dose is 0.4 mg intravenously, intramuscularly, or subcutaneously.

Naloxone dosing depends on the route of administration and the specific product being used. The most widely available community formulations are nasal sprays designed for ease of use by non-medical personnel. Each nasal spray device contains a single dose and should not be primed or tested before use, as this will expel the medication.

Adults — Intranasal (Nasal Spray)

Step-by-Step Administration Guide

The following steps should be followed when administering naloxone nasal spray to a person with suspected opioid overdose:

1. Assess the situation: Check for responsiveness by calling the person's name loudly, shaking their shoulders gently, or rubbing their sternum. Check breathing for 10 seconds — look for chest movement, listen for breath sounds, and feel for air on your cheek.
2. Call emergency services: Call your local emergency number (e.g., 911, 999, 112) immediately, even before administering naloxone. Tell the dispatcher you suspect an opioid overdose.
3. Position the person: Place the person on their back on a flat surface. Ensure the airway is clear by checking for and removing any visible obstructions in the mouth and nose.
4. Open the naloxone package: Remove the nasal spray from its packaging. Do not prime or test the device — it contains only one dose.
5. Administer the spray: Support the back of the neck and tilt the head back slightly. Insert the nozzle into one nostril. Press the plunger firmly until it clicks, delivering the full dose. Remove the nozzle from the nostril.
6. Place in recovery position: Turn the person onto their side (recovery position) to prevent aspiration if they vomit. Stay with them and monitor their breathing.
7. Give a second dose if needed: If there is no improvement after 2-3 minutes, administer a second dose in the other nostril using a new nasal spray device.
8. Continue monitoring: Stay with the person until emergency services arrive. Continue to monitor their breathing and responsiveness. Be aware that overdose symptoms may return after naloxone wears off (30-90 minutes).

Adults — Injectable

Children

The nasal spray formulations described in this article (1.26 mg and 1.8 mg) are approved for use in adults only and should not be used in children or adolescents. In healthcare settings, pediatric naloxone dosing is based on weight: typically 0.01 mg/kg for infants and children, which may be repeated as needed. If a child is suspected of opioid exposure, call emergency services immediately for guidance on appropriate management.

Elderly

No specific dose adjustment is required for elderly patients. However, older adults may be more susceptible to cardiovascular effects of rapid opioid reversal, including hypertension and cardiac arrhythmias. The lowest effective dose should be used, and careful monitoring is advised.

Overdose

Naloxone has an extremely wide safety margin. In clinical studies, doses far exceeding the standard therapeutic dose have been administered without significant adverse effects in individuals who are not opioid-dependent. Naloxone has no intrinsic pharmacological activity in the absence of opioids — it does not produce sedation, respiratory depression, or any psychoactive effects. If administered to someone who has not taken opioids, it will simply have no effect.

If you suspect that a child has accidentally come into contact with naloxone, contact your healthcare provider or poison control center for guidance, though significant harm is unlikely.

What Are the Side Effects of Naloxone?

The most common side effect of naloxone is nausea. Other common effects include dizziness, headache, rapid heartbeat, and changes in blood pressure. In opioid-dependent individuals, naloxone can trigger acute withdrawal syndrome. Rare but serious side effects include cardiac arrhythmias, pulmonary edema, and severe allergic reactions.

It is important to understand that many of the effects observed after naloxone administration are related to the rapid reversal of opioid effects rather than direct toxicity of naloxone itself. Distinguishing between naloxone side effects and opioid withdrawal symptoms can be challenging in clinical practice, as both occur simultaneously in opioid-dependent individuals.

Naloxone has been used safely for over 50 years and has an excellent safety profile. When administered to a person who has not been exposed to opioids, naloxone produces essentially no pharmacological effects. The following side effects are primarily observed in the context of opioid overdose reversal.

The cardiovascular side effects (particularly arrhythmias and cardiac events) are most commonly seen in patients with pre-existing cardiovascular disease and in situations where very large doses of naloxone are administered rapidly. In community overdose reversal with standard nasal spray doses, serious cardiovascular events are exceedingly rare.

If you experience any unexpected effects after receiving naloxone, seek medical attention promptly. Healthcare professionals are encouraged to report any suspected adverse reactions to their national pharmacovigilance authorities.

How Should You Store Naloxone?

Store naloxone at room temperature, away from direct light and extreme heat or cold. Do not freeze. Keep in its original packaging until ready for use. Check the expiration date regularly and replace expired devices. Store out of reach of children.

Proper storage of naloxone is essential to ensure the medication remains effective when needed in an emergency. Naloxone nasal spray should be stored in its sealed plastic protective case until ready for use. The medication is light-sensitive, so keeping it in the original packaging provides necessary protection from degradation.

Store naloxone at room temperature, generally between 15°C and 25°C (59°F and 77°F). Avoid exposing the medication to extreme temperatures. Do not freeze naloxone, as this can damage the delivery mechanism and alter the medication's effectiveness. Brief temperature excursions (such as carrying naloxone in a bag on a hot day) are generally acceptable, but prolonged exposure to extreme heat or cold should be avoided.

Check the expiration date on the packaging regularly — the date is printed on the single-dose container, the protective plastic packaging, and the outer carton. The expiration date refers to the last day of the indicated month. Replace any expired naloxone devices promptly. Community programs and pharmacies may offer free or low-cost replacements.

Keep naloxone out of sight and reach of children. Do not dispose of unused naloxone by flushing it down the toilet or throwing it in household waste. Return unused or expired medications to a pharmacy for proper disposal, which helps protect the environment.

Carrying naloxone

Naloxone should be easily accessible in an emergency. If you are at risk of opioid overdose or know someone who is, carry naloxone with you at all times. Many people keep naloxone in a purse, backpack, glove compartment, or bedside drawer. The key is to ensure it is readily available and that those around you know where to find it.

What Does Naloxone Contain?

Naloxone nasal spray contains the active substance naloxone as the hydrochloride dihydrate salt. Inactive ingredients vary by brand but typically include povidone, glycerol, disodium edetate, benzalkonium chloride, citric acid monohydrate, sodium citrate, sodium hydroxide, hydrochloric acid, and water for injections.

The active substance in naloxone nasal spray is naloxone hydrochloride dihydrate. Each single-dose nasal spray device delivers a precisely measured dose of naloxone — either 1.26 mg, 1.8 mg, or 4 mg, depending on the specific product and market. The naloxone is dissolved in a clear, colorless solution contained in a glass vial within the spray device.

Active ingredient

Naloxone hydrochloride dihydrate — a synthetic derivative of oxymorphone with no intrinsic opioid agonist activity. Molecular formula: C₁₉H₂₁NO₄·HCl·2H₂O. Naloxone was first synthesized in 1960 and has been in clinical use since 1971.

Inactive ingredients (excipients)

The inactive ingredients serve various functions in the formulation:

• Povidone — stabilizer and solubilizing agent
• Glycerol — moisturizer and tonicity agent to prevent nasal irritation
• Disodium edetate (EDTA) — chelating agent to improve stability
• Benzalkonium chloride — preservative (0.02 mg per spray, equivalent to 0.2 mg/ml); may cause nasal irritation with repeated use
• Citric acid monohydrate and sodium citrate — pH buffer system
• Sodium hydroxide and hydrochloric acid — pH adjustment
• Water for injections — solvent

The nasal spray device consists of a glass vial with a rubber stopper inside a polypropylene and stainless steel spray actuator. No additional assembly is required — the device is ready for immediate use when removed from its packaging. Each unit-dose container delivers approximately 0.1 ml of solution.

Where Can You Get Naloxone?

Naloxone is available over-the-counter without a prescription in many countries including the United States, United Kingdom, Australia, Canada, and several EU nations. It can be obtained from pharmacies, harm reduction programs, community health organizations, and in some cases from vending machines and online retailers.

Access to naloxone has expanded dramatically over the past decade as governments and health organizations have recognized its crucial role in combating the opioid overdose crisis. The trend toward greater availability reflects the medication's excellent safety profile and the clear public health benefit of widespread distribution.

In the United States, the FDA approved Narcan (naloxone hydrochloride) 4 mg nasal spray for over-the-counter sale in March 2023, making it the first naloxone product available without a prescription nationwide. Prior to this, many states had already enacted laws allowing pharmacists to dispense naloxone without an individual prescription through standing orders. Naloxone is also distributed free of charge by many community-based organizations and harm reduction programs.

In the European Union, naloxone availability varies by country. Several countries including the United Kingdom, Ireland, Italy, Norway, and Denmark have implemented take-home naloxone programs that provide the medication to individuals at risk and their family members. The specific brand names vary across Europe — for example, it is marketed as Ventizolve in several Nordic countries, Nyxoid in many EU markets, and as Naloxone 1.26 mg in the United Kingdom (Northern Ireland).

In Australia, naloxone nasal spray has been available over-the-counter since 2016, and the government subsidizes its cost through the Pharmaceutical Benefits Scheme (PBS). Canada also provides naloxone without prescription through pharmacies and community programs across all provinces and territories.

Many organizations worldwide provide naloxone kits free of charge to individuals who use opioids, their family members, and community members. These programs typically include training on how to recognize overdose signs and how to administer the medication.